Zevra Therapeutics, Inc.
ZVRA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.36 | 1.08 | -0.06 |
| FCF Yield | -0.79% | -2.05% | -3.63% | -5.47% |
| EV / EBITDA | -7.00 | 252.60 | -28.69 | -11.53 |
| Quality | ||||
| ROIC | -30.27% | -1.40% | -18.67% | -17.27% |
| Gross Margin | 52.17% | 93.41% | 88.66% | 37.67% |
| Cash Conversion Ratio | -8.66 | -0.05 | 2.65 | 0.45 |
| Growth | ||||
| Revenue 3-Year CAGR | 71.06% | 54.43% | 61.31% | 31.19% |
| Free Cash Flow Growth | 54.16% | 48.79% | 10.42% | 5.07% |
| Safety | ||||
| Net Debt / EBITDA | -0.21 | 14.40 | -1.60 | -0.20 |
| Interest Coverage | -35.36 | -2.72 | -7.03 | -21.62 |
| Efficiency | ||||
| Inventory Turnover | 11.17 | 0.53 | 0.69 | 0.00 |
| Cash Conversion Cycle | -43.60 | -965.45 | -653.13 | -766.30 |